Tumor Immunotherapy Using A2A Adenosine Receptor Antagonists

被引：20

作者：

Zhang, Jinfeng ^{[1
,2
]}

Yan, Wenzhong ^{[1
]}

Duan, Wenwen ^{[1
]}

Wuthrich, Kurt ^{[1
,3
]}

Cheng, Jianjun ^{[1
]}

机构：

[1] ShanghaiTech Univ, IHuman Inst, Shanghai 201210, Peoples R China

[2] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China

[3] Scripps Res, Dept Integrated Struct & Computat Biol, La Jolla, CA 92037 USA

来源：

PHARMACEUTICALS | 2020年 / 13卷 / 09期

关键词：

GPCR; immuno-oncology; Parkinson's disease; drug binding modes; cancer therapy; PARKINSONS-DISEASE; CRYSTAL-STRUCTURE; DERIVATIVES; ZM241385; POTENT; ZM-241385; BLOCKADE; BINDING; CELLS;

D O I：

10.3390/ph13090237

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The A(2A) adenosine receptor (A(2A) AR) plays critical roles in human physiology and pathophysiology, which makes it an important drug target. Previous drug-discovery efforts targeting the A(2A) AR have been focused on the use of A(2A) AR antagonists for the treatment of Parkinson's disease. More recently, the A(2A) AR has attracted additional attention for its roles in immuno-oncology, and a number of A(2A) AR antagonists are currently used as lead compounds for antitumor drugs in both preclinical models and clinical trials. This review surveys recent advances in the development of A(2A) AR antagonists for cancer immunotherapy. The therapeutic potential of representative A(2A) AR antagonists is discussed based on both animal efficacy studies and clinical data.

引用

页码：1 / 14

页数：14

共 50 条

[41] Adenosine A2A receptor as a potential target for improving cancer immunotherapy
Muhammad Atif
Abdullah Alsrhani
Farrah Naz
Muhammad Ikram Ullah
Ayman Ali Mohammed Alameen
Muhammad Imran
Hasan Ejaz
Molecular Biology Reports, 2022, 49 : 10677 - 10687
[42] Adenosine A2A receptor as a potential target for improving cancer immunotherapy
Atif, Muhammad
Alsrhani, Abdullah
Naz, Farrah
Ullah, Muhammad Ikram
Alameen, Ayman Ali Mohammed
Imran, Muhammad
Ejaz, Hasan
MOLECULAR BIOLOGY REPORTS, 2022, 49 (11) : 10677 - 10687
[43] Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists
Petzer, JP
Steyn, S
Castagnoli, KP
Chen, JF
Schwarzschild, MA
Van der Schyf, CJ
Castagnoli, N
BIOORGANIC & MEDICINAL CHEMISTRY, 2003, 11 (07) : 1299 - 1310
[44] Adenosine receptor A2A antagonists as neuroprotective agents:: Possible involvement of calcium
Royak, Y
Mandel, S
Bick, T
Green, J
Jacobson, KA
Youdim, MBH
NEUROSCIENCE LETTERS, 1999, : S35 - S35
[45] Studies on adenosine A2a receptor antagonists:: comparison of three core heterocycles
Vu, CB
Pan, D
Peng, B
Sha, L
Kumaravel, G
Jin, XW
Phadke, D
Engber, T
Huang, C
Reilly, J
Tam, S
Petter, RC
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (19) : 4831 - 4834
[46] Adenosine A2A Receptor Antagonists as a Treatment Option for Parkinson's Disease?
Jost, Wolfgang H.
Toenges, Lars
FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2022, 90 (12) : 565 - 570
[47] Novel therapy in Parkinson's disease: adenosine A2A receptor antagonists
Szabo, Nikoletta
Kincses, Zsigmond Tamas
Vecsei, Laszlo
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2011, 7 (04) : 441 - 455
[48] A2A adenosine receptor antagonists -: future drugs for Parkinson's disease?
Müller, CE
DRUGS OF THE FUTURE, 2000, 25 (10) : 1043 - 1052
[49] Novel Quinazoline Derivatives as Highly Effective A2A Adenosine Receptor Antagonists
Laversin, Amelie
Dufossez, Robin
Bolteau, Raphael
Duroux, Romain
Ravez, Severine
Hernandez-Tapia, Sergio
Fossart, Martin
Coevoet, Mathilde
Liberelle, Maxime
Yous, Said
Lebegue, Nicolas
Melnyk, Patricia
MOLECULES, 2024, 29 (16):
[50] Design, synthesis, and biological evaluation of novel adenosine A2A receptor antagonists
Silverman, LS
Caldwell, J
Greenlee, WJ
Kiselgof, EY
Matasi, J
Tuishian, D
Arik, L
Foster, C
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2548 - U2549

← 1 2 3 4 5 →